Immunotherapy before colon cancer surgery study
Treatments studied
Part of Cancer clinical trials.
This trial tests two immunotherapy drugs, zanzalintinib and retifanlimab, given before surgery to remove colon cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes for people with a specific type of colon cancer (called pMMR/MSS).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have colon cancer that can be removed with surgery and has not spread beyond the colon and nearby lymph nodes.
- Your tumor type is pMMR/MSS (your doctor can check this).
- You have not had immunotherapy (immune checkpoint blockers) or certain other cancer treatments in the last 2 years.
- You are in generally good health (able to do your daily activities without help) and have adequate kidney, liver, and blood cell counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests immunotherapy plus chemotherapy given before surgery for colon cancer that hasn’t spread. It aims to shrink or control the tumor and improve outcomes in people whose tumor has certain immune/biologic features.
This trial tests two immunotherapy drugs (cemiplimab and fianlimab) before surgery for colon cancer that hasn't spread. It's for people with a specific tumor type (pMMR/MSS) who are candidates for surgery.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests a new immunotherapy drug (AK104) given before and after surgery for a specific type of colon cancer that is MSI-H or dMMR. The goal is to see if the drug helps shrink the tumor and prevent the cancer from coming back.
This trial tests if the immunotherapy drug pembrolizumab can shrink colon cancers with specific genetic features (dMMR/MSI-H) before surgery. If the tumor responds well, some patients might avoid chemotherapy after surgery. It is for people with newly diagnosed, localized colon or upper rectal cancer.
This trial tests a new immunotherapy drug (tislelizumab) given before surgery for people with stage II or III colorectal cancer that has a specific DNA repair problem (dMMR/MSI-High). The drug aims to shrink the tumor and improve treatment outcomes.
Hear when a new Colon Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.